The association of HLA-B27 with ankylosing spondylitis (AS) is the strongest among all inflammatory diseases. However, the exact role of these molecules in disease pathogenesis is still unknown. The existence of HLA-B27 variants rarely found in patients introduces a further level of complexity. It is now accepted that other genes of minor impact contribute to modify disease susceptibility and these genes might be diverse in different populations depending on the genetic background. We report here a study performed in Sardinia, an outlier population in which two major HLA-B27 subtypes are present, B *2705 strongly associated with AS and B *2709 which is not, and show the co-occurrence of the B *2705 allele with a single nucleotide polymorphism (SNP) mapping at 3 0 -UTR of the receptor 1 (VIPR1) for the vasoactive intestinal peptide (VIP), a neuropeptide with anti-inflammatory properties. This same SNP is associated with a different kinetics of down-modulation of the VIPR1 mRNA in monocytes after exposure to lipopolysaccharide (P ¼ 0.004). This particular setting, HLA-B *2705 and a functional polymorphism in VIPR1 gene, might be due to a founder effect or might be the result of a selective pressure. Irrespectively, the consequent downregulation of this receptor in the presence of a 'danger' signal might influence susceptibility to AS.
Introduction
Vasoactive intestinal peptide (VIP) is a 28mer pleiotropic neuropeptide involved in the maintenance of neuroendocrine immune systems communication. 1 VIP exerts a broad range of biological functions through specific receptors also present on immune cells. These receptors belong to the group II of G-protein-coupled receptors, the secretin receptor family. 2 VIP, when released in the lymphoid organs by nerve stimuli and by activated immune cells, modulates the function of inflammatory cells through its receptors, thus affecting both innate and adaptive immunity. 3, 4 Accordingly, VIP has been described as an effective therapeutic agent in several animal models of inflammatory/autoimmune diseases, such as inflammatory bowel disease, collagen-induced arthritis, experimental autoimmune encephalomyelitis, endotoxic shock, Parkinson's disease and Sjogren's disease. [5] [6] [7] [8] [9] [10] However, its translation to the clinic and its application in the corresponding human diseases is still far off.
The human type 1 receptor for VIP (VIPR1) gene maps on human chromosome 3 and is highly conserved through species. 2 Interestingly, VIPR1 has been reported to be down-modulated in cells of the immune system after activation. 11 This is compatible with a role for this molecule in hampering the correct order of events orchestrating the inflammatory response.
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease exhibiting a strong genetic component. 12 The major susceptibility factor is HLA-B27, whose role in pathogenesis has not been fully understood. 13, 14 Moreover, although HLA-B27 is present in the high majority of patients with AS, it has been reported that the HLA region accounts for only 20-50% of the genetic contribution calculated in more than 90% by twin variance model. 15 Accordingly, the effect of additional genes of minor impact within and outside the HLA region is generally acknowledged. 16 Sardinian population is considered an outlier population with genetic features making it highly informative for association studies. 17, 18 Accordingly, AS in Sardinia co-segregates with a highly conserved HLA haplotype (A2, B *2705, DR16) shared by 92% of patients. 19 A further reason that makes Sardinian population particularly amenable to study AS, is the presence of two major HLA-B27 alleles, B *2705 and B *2709. The latter, that segregates with a different haplotype, has been rarely found in patients. 20, 21 Interestingly, the two HLA-B27 molecules, B *2705 and B *2709, bind differently a peptide derived from VIPR1 (pVIPR1 aa 400-408) 22 that could explain the pVIPR1-specific autoreactivity present in B *2705 but not in B *2709-positive individuals 23 (MT Fiorillo, unpublished data). Therefore VIPR1 represents an interesting candidate gene for association studies in AS although, in a genome-wide map, no linkage has been found between AS and p22 region of chromosome 3 where VIPR1 gene maps.
2 Accordingly, we have analysed VIPR1 single nucleotide polymorphisms (SNPs) frequencies in HLA-B *2705 positive both patients with AS and controls versus random controls in Sardinia. The results indicate that HLA-B *2705, independently from the disease, co-occurs more frequently with allele T at the SNP rs896 in the 3 0 UTR of VIPR1 gene (72% of HLA-B *2705 individuals possess at least one T at rs896 vs 58% of random controls, P ¼ 0.001). These data prompted us to verify whether this polymorphism correlates with a function. The results show that the presence of allele T at rs896 strongly influences the kinetics of downregulation of the VIP receptor 1 in monocytes exposed to lipopolysaccharide (LPS).
Results
Co-occurrence of HLA-B *2705 with allele T at SNP rs896 of VIPR1 gene Allele frequencies of four SNPs mapping in the VIPR1 gene were analysed in a Sardinian control population (N ¼ 261). Genotype distribution was in Hardy-Weinberg equilibrium for all SNPs. Linkage disequilibrium (LD) values of adjacent SNPs were the highest for rs896-rs342511: (r 2 ¼ 0.64), lower for rs437876-rs896 (r 2 ¼ 0.17) and the lowest for rs896-rs9677 (r 2 ¼ 0.09). Allele and genotype frequencies at the four SNPs in HLA-B *2705-positive patients with AS (N ¼ 110) and in B *2705 controls (N ¼ 104) were similar with the only exception of genotype T/T at rs9677 that is 19% in the B *2705 controls and 30% in the patients with AS (P ¼ NS). We therefore considered the two B *2705-positive cohorts as a single one in the statistical analysis. Allele distribution at rs896 is different in the B *2705-positive cohort compared to random controls (allele C at rs896: 55 versus 65%; P ¼ 0.001, pc ¼ 0.01, OR ¼ 0.65; 95% CI ¼ 0.5-0.85) ( Table 1) . Genotype distribution at rs896 is also different with a significant Cochrane-Armitage test for trend (P ¼ 0.003). The number of subjects possessing at least one T at rs896 is also significantly higher in the B *2705-positive cohort than in the random controls (72 versus 58%; P ¼ 0.001, OR ¼ 1.9; 95% CI ¼ 1.3-2.8). When the three SNPs (rs437876, rs896 and rs342511) showing higher LD are taken into account, haplotype analysis (Table 2) shows a prevalence of the GTG combination in the HLA-B *2705-positive cohort (P ¼ 0.005) and a parallel decrease of the GCA haplotype (P ¼ 0.01), pointing again at rs896 as the relevant polymorphism among those analysed. To verify that the association was due to the presence of HLA-B *2705 allele, we analysed: (1) a small cohort of 58 HLA-B27-positive subjects typed as HLA-B27 but not B *2705. As shown in Table 1 , genotype distribution was very similar to that of the random controls. (2) An additional cohort of 118 controls for genotype distribution of the two SNPs co-amplified in the same PCR fragment: rs896 and rs9677. In this case as well, genotype distribution was not significantly different from that in the random controls.
As a measure of whether the differences reported here were not due to population stratification, genotype distribution of an SNP mapping at 5 0 end (position -13910; rs4988235) of the gene for lactase was also analysed. This polymorphism has been reported to vary considerably from northwestern to southeastern Europe and differences in allele frequencies between cases and controls indicate population stratification. 24 The results (Table 3) do not show a significant difference in the allelic frequencies of this SNP between random controls and the HLA-B27 cohorts and the frequency of the C allele is around 0.9 as already reported for the Sardinian population. 25 Down-modulation of VIPR1 mRNA correlates with a 3 0 -UTR polymorphism VIPR1 is known to be down-modulated in immune cells such as T lymphocytes or monocytes after stimulation. Monocytes have a relevant role in inflammation and respond quickly to bacterial exposure. Moreover they express VIPR1 as the only receptor for VIP. 11 LPS, an endotoxin expressed by Gram-negative bacteria, is a powerful activator of the inflammatory response in monocytes. Monocytes from five donors were then exposed to LPS for 0, 3, 6, 9 and 12 h. Afterwards, the amount of VIPR1-specific mRNA has been evaluated by quantitative PCR. A high variability of VIPR1 mRNA in untreated monocytes from different subjects has been noticed, probably reflecting the basal activation of monocytes ( Figure 1 ). However, two kinetics by which VIPR1 mRNA was downregulated after LPS stimulation could be envisaged: one in which a reasonable high level (450%) of mRNA was maintained through time (subjects A and C) and a second one in which the decrease of the mRNA was pronounced (B, D and E). After 12 h, in some cases there is a trend to restore the amount of mRNA to the level before LPS treatment (A, D), in some others remains low. The experiments were repeated using monocytes from 53 donors that had been typed for the four SNPs along the VIPR1 gene. Nine hours time point was chosen as the most representative to evaluate the percentage of down-modulation of the VIPR1 mRNA after LPS exposure. Depending on the number of monocytes rescued, in some cases (n ¼ 27) the evaluation has been performed also at 3 h time point. The percentage of the specific mRNA in LPS-treated monocytes was compared to untreated cells. The correlation between VIPR1 mRNA and three SNPs: rs437876, rs896 or rs9677 genotypes has been analysed at 3 h ( Figure 2a ) and at 9 h (Figure 2b ) after LPS stimulation. The most significant correlation (P ¼ 0.004) takes place between the presence of a T at rs896 and a sharp decrease of VIPR1 transcript after 9 h from LPS exposure (Figure 2b ). Rs9677 maps only 526 bp downstream rs896 but shows a low LD with it. The two SNPs have been amplified in the same PCR fragment and processed together thus representing a valuable reciprocal quality control: rs9677 does not show any trend of correlation. The same analysis at 3 h after LPS exposure reveals also a correlation between the down-modulation of VIPR1 and rs896 that, interestingly, is higher for the T/T than for the C/T genotype, suggesting a small gene dosage (33) 19 (20) 25 (53) 26 (15) 26 (31) Abbreviations: NS, not significant; SNP, single nucleotide polymorphism.
Vasoactive intestinal peptide receptor 1 and HLA-B27 F Paladini et al effect on the kinetics of the mRNA downregulation. After 9 h however, the difference between the heterozygous (C/T) and the homozygous (T/T) status is not anymore detectable and the presence of T at rs896 strongly correlates with a low residual amount of VIPR1 mRNA.
VIPR1 protein analysis
To verify whether the mRNA downregulation determines an effective lower amount of VIPR1 receptor protein, western blot analysis was performed using monocytes from three subjects homozygous for C and 3 for T at rs896 exposed to LPS for 6, 9 and 12 h (Figure 3) . After 9 h of LPS treatment, the VIPR1 protein is decreased of about 40% in monocytes typed as T/T at rs896, whereas monocytes C/C homozygous at rs896 maintain a high level of expression.
Discussion
Common genetic variations contribute appreciably to differences in phenotypes, and therefore are likely to be involved in many complex genetic diseases. We show here that one such variant (rs896) mapping at the 3 0 -UTR of the VIPR1 gene correlates with a different kinetics of its mRNA downregulation in activated monocytes. These mononuclear cells express a relatively high, albeit variable, amount of VIPR1 mRNA as unique receptor for VIP 11 and are equipped to respond promptly to (26) 9 (10) 13 (13) 14 ( bacterial, inflammatory stimuli. When stimulated with LPS, they are able to down-modulate the expression of VIPR1 transcript in a manner that correlates with the rs896 variation. VIPR1 down-modulation has been also demonstrated in T lymphocytes after a strong stimulus such as the engagement of CD3 with a specific antibody. 11 This has been correlated with the anti-inflammatory properties of VIP as signalling through VIPR1 Vasoactive intestinal peptide receptor 1 and HLA-B27 F Paladini et al inhibits nuclear factor-kB activation. 26 Accordingly, VIP has been reported to protect mice from lethal endotoxemia, presumably by downregulating endogenous pro-inflammatory macrophage-derived mediators, 27 to inhibit the production of several pro-inflammatory cytokines [28] [29] [30] [31] and chemokines such as IL-8, 26 and to exert a protective effect in some models of autoimmune diseases. [5] [6] [7] [8] [9] [10] It has been speculated that the suppressive effect on VIPR1 transcription can be mediated by a cis-regulatory repressor element located on the gene. Pei cloned a repressor protein that downes VIPR1 expression in rats, 32 however, a homologous VIPR1 repressor protein in humans has not been identified as yet. It has been postulated that the down-modulation of VIPR1 after T-cell activation may be mediated by Ikaros transcription factor. 33 Our data show that the 3 0 -UTR also has an important role. This is not surprising, since posttranscriptional regulation provides a mean to rapidly alter gene expression in response to diverse stimuli, and it is frequently observed in genes encoding proteins with essential cellular functions such as proliferation and stress response. It is possible that rs896 is a marker for this association as there are other SNPs in the region showing a complete or a very strong LD with it. 34 Noteworthy however, SNP rs896 (C/T) is located in the middle of a stretch of UA-rich sequence (UUUUU/ CAAA) where a C interrupts the UA sequence. This interruption is likely to modify the RNA secondary structure and possibly the binding of a protein that might be induced by LPS, as the effect of this polymorphism, already visible after 3 h, becomes more evident at 9 h after LPS exposure. This timing is in agreement with what reported for T lymphocytes. 11 The control of mRNA stability is a potent regulatory mechanism, as small changes in mRNA half-life result in a remarkable variation in the mRNA available for translation into functional protein as also shown here. [35] [36] [37] [38] Notably, the same allele associated with a more efficient downregulation is also significantly increased in the cohort of HLA-B *2705-positive individuals in Sardinia, an allele strongly associated with AS. How HLA-B27 influences disease pathogenesis is unknown, but it is becoming more and more evident that several distinct features of these molecules can be involved. Our findings of the co-occurrence of HLA-B *2705 allele with a more efficient downregulation of the VIPR1 mRNA and, therefore, with a lower amount of receptor available for VIP and its anti-inflammatory properties, could influence disease evolution. It must be noticed however, that this association is not limited to patients, but stands also for the B *2705-positive cohort with no sign of disease. It is also of note that in a small cohort of 58 individuals carrying B27 alleles other than B *2705 (mainly B *2709), we did not find any difference from the controls in the genotype distribution of rs896, reinforcing the idea that the association of allele T at rs896 is HLA-B *2705-specific. This particular setting of an HLA haplotype and a functional polymorphism in a gene involved in the regulation of the immune response but mapping in a different chromosome could be due to a founder effect or can be the result of a selection operated in Sardinia by endemic parasite diseases such as malaria. 39 This would not be surprising as it has been demonstrated that several genes have undergone to selection by Plasmodium falciparum endemic in Sardinia, among which immune response genes and that this might represent a favourable immunogenetic background for some autoimmune diseases, as suggested for multiple sclerosis. 40 Noteworthy, a recent paper has reported a genetic association between polymorphisms mapping at the 3 0 end of the VIPR1 gene and rheumatoid arthritis 34 confirming both the relevance of this region in the regulation of the VIPR1 gene expression and of the VIP/VIPR1 signalling pathway in modulating the tolerance in rheumatic, inflammatory diseases.
Materials and methods

Subjects
A total of 110 HLA-B *2705-positive patients with diagnosis of AS according to the modified New York criteria have been selected in Cagliari, Sardinia. The majority of them has been reported in other studies. 20, 21 Random controls (N ¼ 261) and HLA-B *2705 positive (N ¼ 104) were blood donors recruited from Sardinia. Patients with AS were 75% men and controls were therefore balanced for gender (72% men). All patients and controls gave their informed consent. Two further cohorts of 118 controls and 58 HLA-B27 positive other than B *2705 individuals were subsequently selected. The latter were as follows: 37 were B *2709, 11 were B *2702, 8 B *2707 and 2 B *2713. Of these, the majority (N ¼ 46) were healthy individuals and only 12 patients with AS, as the high majority of the latter are typed as B *2705.
SNP typing
The following SNPs: rs437876 (A/G) in intron 4; rs896 (C/T), rs342511 (A/G) and rs9677 (C/T) in the 3 0 -end 0 . Genotype was performed by minisequencing; the amplified products were treated with 0.5 U of shrimp alkaline phosphatase (SAP) (Roche Applied Science, IN, USA) and 2.5 U of exonuclese I (EXO I) (BioLabs) at 37 1C for 120 min and at 75 1C for 15 min for inactivation. For minisequencing reactions, the commercial fluorescent-based minisequencing kit SNaPshot multiplex (Applied Biosystems, Foster City, CA, USA) was used, with 2 pmol of primer. The sequence of the SNaPshot primer was 5 0 -atacagataagataatgtag-3 0 . After the extension and labelling reaction, the unincorporated dNTPs were removed by enzymatic treatment using 0.5 U of SAP at 37 1C for 120 min and at 75 1C for 15 min for inactivation. The products were analysed on the ABI prism 310 Genetic Analysers. Genotyping was performed by 310 ABI Prism GeneScan 2.1 software (Applied Biosystems).
Monocyte purification
Monocytes, separated from PBMC of 53 blood donors, were sorted using the Monocyte Isolation kit and Depletion Column Type LS (Miltenyi Biotec, Auburn, CA, USA) according to the supplier's instructions. Cells viability as measured by Trypan blue exclusion always exceeded 95%. Monocyte purification was higher than 90% as assessed by flow cytometry on a FACScan flow cytometer (FACsort; Becton Dickinson, Sparks, MD, USA) defined by forward and side scatter properties, as well as by staining with anti-CD14 monoclonal antibody (BD Pharmingen, San Diego, CA, USA). Cells were seeded at concentration of 10 6 cells per ml and suspended in RPMI 1640 supplemented with 10% human serum, 2 mM L-glutamine, 25 U ml À1 penicillin and 25 U ml À1 streptomycin (all purchased from Gibco, Invitrogen, Carlsbad, CA, USA) in cell culture plates at 37 1C in a humidified 7% CO 2 incubator in the presence of LPS (0.05 mg ml À1 ) for the indicated time.
Quantitative PCR analysis Total RNA was isolated from cell pellets by TRIzol reagent (Invitrogen, Carlsbad, CA, USA) as recommended. After denaturation of freshly prepared RNAs (approximately 2 mg) at 65 1C for 5 min, SuperScript III Reverse Transcriptase (Invitrogen) was used for oligodT-primed first-strand cDNA synthesis. For measurement of the relative level of expression of VIPR1 in untreated and LPS-stimulated monocytes, real-time RT-PCR was performed using the 7300 Real-Time PCR System (Applied Biosystems (ABI)). Reactions were performed in a Micro-Amp Optical 96-well reaction plates (ABI) using 2.5-ml cDNA of treated or untreated monocytes, in triplicate wells, 12.5 ml of 2 Â Master Mix (ABI), 1.25 ml of validated Assay on Demand gene expression (ABI, HS00270351). The final volume of the PCR was 25 ml. The PCR was performed using the following amplification scheme: one cycle of 10 min at 95 1C followed by 60 cycles of denaturation for 15 s at 95 1C and an annealing/extension step of 1 min at 60 1C. All reactions were conducted using a 7300 Sequence Detector thermocycler linked to a PC using the Sequence Detector software (ABI). Glyceraldehyde-3-phosphate dehydrogenase assay on demand (ABI, HS 99999905) was used to ensure quality of RNA preparation, to account for efficiency of the reverse transcription and to check for any loading variation of the initial cDNA amount.
Western blot analysis After 0, 3, 6, 9 and 12 h of culture in presence of LPS (0.05 mg ml À1 ), monocytes were washed twice with phosphate-buffered saline and lysed in ice-cold radioimmuno precipitation assay buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, 0.5 mM NaVO 4 , 50 mM NaF, 1 mM phenylmethylsulphonylfluoride and a cocktail of protease inhibitors; Roche). Cells debris were removed by centrifugation at 20 000 g for 15 min at 4 1C. Protein concentration in whole-cell extracts was measured by Bradford assay (Bio-Rad, Munich, Germany) with bovine serum albumin used as standard. Cell lysate was mixed with an equal volume of 2 Â electrophoresis sample buffer (125 mM Tris-HCl, pH 6.8, 4% w/v SDS, 20% glycerol, 100 mM dithiothreitol, 0.02% bromophenol blue) and boiled for 5 min. Total protein extract (30 mg) for each sample was separated by 12% SDS-polyacrylamide gel electrophoresis and subsequently transferred to nitrocellulose membrane (Amersham, Piscataway, NJ, USA). After 1 h in Tris-buffered saline tween-20 10% non-fat milk, the membranes were incubated overnight at 4 1C with a polyclonal anti-VIP receptor 1 antibody, a kind gift from Dr Kathleen Freson, Center for Molecular and Vascular Biology, University of Leuven, Belgium 41 and detected by horseradish peroxidase-conjugated goat anti-rabbit secondary antibody using the ECL Western Blotting Detection Kit (Amersham Biosciences). a-Tubulin monoclonal antibody (1:10.000; Santa Cruz Biotec, Santa Cruz, CA, USA) was used to ensure equal protein loading. The intensity of bands was quantified by densitometric analysis using the program UN-SCAN-IT gel (Silk Scientific Inc., Orem, UT, USA). Results were evaluated as the ratio of intensity of VIPR1 to that of a-tubulin from the same sample.
Statistical analysis
Allele frequencies of SNP genotypes were compared by two-tail Fisher's exact test. Bonferroni correction for multiple comparisons was performed. The HardyWeinberg equilibrium was tested by comparing expected to observed genotype frequencies by w 2 -test. CochraneArmitage trend test was performed using StatXact7 software. LD was inferred by Haploview that uses a two-marker EM (ignoring missing data) to estimate the maximum-likelihood values of the four gamete frequencies, from which the D 0 , LOD and r 2 calculations derive. Mann-Whitney unpaired test was used to evaluate the difference in the VIPR1 mRNA down-modulation.
